Daryl C McHugh1, Shannon Lancaster1, Louis N Manganas1. 1. Department of Neurology and the Neurosciences Institute, Stony Brook University Medical Center, Stony Brook, New York, United States.
Abstract
OBJECTIVE: Seizures are the most common neurological complication in neonatal intensive care units. Phenobarbital (PB) remains the first-line antiepileptic drug (AED) for neonatal seizures despite known neurotoxicity. Levetiracetam (LEV) is a newer AED not approved for neonates. Retrospective and pilot studies have investigated the use of LEV in neonatal seizures. Our objective was to compare the efficacy of LEV to PB in neonatal seizures based upon published data. METHODS: We searched PubMed to perform a systematic review. We found no studies of LEV with comparison or control groups; therefore, we utilized data from two randomized controlled trials of PB as our comparison group. RESULTS: Five studies of LEV met all inclusion/exclusion criteria. The pooled sample size for LEV was 102 (48 received primary LEV, 54 received secondary LEV). The pooled sample size for primary PB was 52. Complete or near-complete seizure cessation was achieved as follows: primary LEV 37/48 (77%), secondary LEV 34/54 (63%), and primary PB 24/52 (46%). CONCLUSION: Our findings suggest that LEV may be at least as or more effective for neonatal seizures as PB. Our review, though limited, is the first to examine LEV efficacy compared with PB in neonates. Georg Thieme Verlag KG Stuttgart · New York.
OBJECTIVE: Seizures are the most common neurological complication in neonatal intensive care units. Phenobarbital (PB) remains the first-line antiepileptic drug (AED) for neonatal seizures despite known neurotoxicity. Levetiracetam (LEV) is a newer AED not approved for neonates. Retrospective and pilot studies have investigated the use of LEV in neonatal seizures. Our objective was to compare the efficacy of LEV to PB in neonatal seizures based upon published data. METHODS: We searched PubMed to perform a systematic review. We found no studies of LEV with comparison or control groups; therefore, we utilized data from two randomized controlled trials of PB as our comparison group. RESULTS: Five studies of LEV met all inclusion/exclusion criteria. The pooled sample size for LEV was 102 (48 received primary LEV, 54 received secondary LEV). The pooled sample size for primary PB was 52. Complete or near-complete seizure cessation was achieved as follows: primary LEV 37/48 (77%), secondary LEV 34/54 (63%), and primary PB 24/52 (46%). CONCLUSION: Our findings suggest that LEV may be at least as or more effective for neonatal seizures as PB. Our review, though limited, is the first to examine LEV efficacy compared with PB in neonates. Georg Thieme Verlag KG Stuttgart · New York.
Authors: Cynthia Sharpe; Gail E Reiner; Suzanne L Davis; Mark Nespeca; Jeffrey J Gold; Maynard Rasmussen; Rachel Kuperman; Mary Jo Harbert; David Michelson; Priscilla Joe; Sonya Wang; Neggy Rismanchi; Ngoc Minh Le; Andrew Mower; Jae Kim; Malcolm R Battin; Brian Lane; Jose Honold; Ellen Knodel; Kathy Arnell; Renee Bridge; Lilly Lee; Karin Ernstrom; Rema Raman; Richard H Haas Journal: Pediatrics Date: 2020-05-08 Impact factor: 7.124
Authors: Charlotte B Wagner; Alexander M Kreimer; Nina P Carrillo; Elizabeth Autry; Aric Schadler; Aaron M Cook; Noelle R Leung Journal: J Pediatr Pharmacol Ther Date: 2021-02-15
Authors: Laurent M A Favié; Floris Groenendaal; Marcel P H van den Broek; Carin M A Rademaker; Timo R de Haan; Henrica L M van Straaten; Peter H Dijk; Arno van Heijst; Sinno H P Simons; Koen P Dijkman; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Johanna H van der Lee; Debbie H G M Nuytemans; Frank van Bel; Toine C G Egberts; Alwin D R Huitema Journal: Neonatology Date: 2019-06-28 Impact factor: 4.035
Authors: Jennifer C Keene; Mark Wainwright; Lindsey A Morgan; Ulrike Mietzsch; Ndidi Musa; Xiuhua L Bozarth; Niranjana Natarajan Journal: J Pediatr Pharmacol Ther Date: 2022-03-21